Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis

• Published in: Arthritis and rheumatism 2005-01, Vol.52 (1), p.171-180
• Main Authors: Sabatini, Massimo, Lesur, Christophe, Thomas, Marie, Chomel, Agnès, Anract, Philippe, de Nanteuil, Guillaume, Pastoureau, Philippe
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Cartilage, Articular - drug effects; Cartilage, Articular - enzymology; Cartilage, Articular - metabolism; Cartilage, Articular - pathology; Disease Models, Animal; Diseases of the osteoarticular system; Epiphyses - pathology; Guinea Pigs; Humans; In Vitro Techniques; Knee Joint - enzymology; Knee Joint - pathology; Male; Matrix Metalloproteinase Inhibitors; Medical sciences; Miscellaneous. Osteoarticular involvement in other diseases; Osteoarthritis; Osteoarthritis - enzymology; Osteoarthritis - metabolism; Osteoarthritis - pathology; Protease Inhibitors - pharmacology; Proteoglycans - metabolism; Pyridines - pharmacology; Rabbits; Sulfones - pharmacology; Tibia - pathology
• ISSN: 0004-3591; 1529-0131
• DOI: 10.1002/art.20900

Objective To study the effects of a matrix metalloproteinase (MMP) inhibitor (S‐34219) on osteoarthritis (OA) cartilage cultures and in the meniscectomized guinea pig model of OA. Methods The inhibitory activity of S‐34219 on MMPs and aggrecanase was studied by fluorimetry and immunoassay, respectively. The effects of S‐34219 on proteoglycan and collagen degradation were studied in cultures of rabbit and human cartilage. Medial meniscectomy was performed on 29 Hartley male guinea pigs, and these animals were randomly allocated to 1 of 3 groups: a control meniscectomized group (MNXc) receiving the vehicle, or a meniscectomized group receiving either 10 mg/kg or 20 mg/kg S‐34219, administered twice per day by oral gavage for 12 weeks from day 1 after surgery. An additional group comprised sham‐operated animals. Tibial cartilage from the operated left knee was processed for histologic assessment of OA lesions. Results The 50% inhibitory concentration (IC50) of S‐34219 on MMPs 1, 2, 3, 8, 9, and 13 was 55, 0.1, 0.5, 0.1, 0.03, and 0.2 nM, respectively; the IC50 on aggrecanase 1 was 190 nM. In cultured rabbit cartilage, 100 nM S‐34219 strongly inhibited MMP‐dependent degradation of collagen and proteoglycans. A concentration 100 times higher was needed to inhibit aggrecanase‐dependent degradation. In cultures of human OA cartilage, 100 nM S‐34219 inhibited spontaneous type II collagen degradation by 66% and proteoglycan degradation by only 22%. For in vivo studies, treated groups were compared with the MNXc group and the results, expressed as the percentage variation versus MNXc, were as follows: in the 10 and 20 mg/kg groups, a significant decrease (P < 0.05) in global histologic score (−12% and −14%, respectively) was observed, and this was associated with a significant increase (P < 0.05) in cartilage thickness (+19% and +18%, respectively). Neither dose level changed the proteoglycan content. Conclusion In both treated animal groups, S‐34219 significantly prevented the loss of cartilage thickness, probably by inhibiting collagen breakdown that normally leads to the erosion of fibrillated superficial areas. The absence of a protective effect on glycosaminoglycan loss, both in vitro and in vivo, suggests that aggrecanases may have an important role in cartilage loss. This study reinforces the relevance of these models for testing chondroprotective drugs, and the potential role of dual inhibitors of collagenase and aggrecanase as disease‐modifying drugs in the